AU2013295770A1 - Tick toxin compositions - Google Patents

Tick toxin compositions Download PDF

Info

Publication number
AU2013295770A1
AU2013295770A1 AU2013295770A AU2013295770A AU2013295770A1 AU 2013295770 A1 AU2013295770 A1 AU 2013295770A1 AU 2013295770 A AU2013295770 A AU 2013295770A AU 2013295770 A AU2013295770 A AU 2013295770A AU 2013295770 A1 AU2013295770 A1 AU 2013295770A1
Authority
AU
Australia
Prior art keywords
peptide
seq
amino acid
holocyclus
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2013295770A
Other languages
English (en)
Inventor
Andrew George ALLEN
Georgia DELIYANNIS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zoetis Services LLC
Original Assignee
Zoetis Services LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services LLC filed Critical Zoetis Services LLC
Publication of AU2013295770A1 publication Critical patent/AU2013295770A1/en
Priority to AU2017261603A priority Critical patent/AU2017261603B2/en
Priority to AU2019204773A priority patent/AU2019204773B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43527—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from ticks
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Insects & Arthropods (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2013295770A 2012-07-27 2013-07-25 Tick toxin compositions Abandoned AU2013295770A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2017261603A AU2017261603B2 (en) 2012-07-27 2017-11-17 Tick toxin compositions
AU2019204773A AU2019204773B2 (en) 2012-07-27 2019-07-03 Tick toxin compositions

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261676384P 2012-07-27 2012-07-27
US61/676,384 2012-07-27
PCT/US2013/051988 WO2014018724A1 (fr) 2012-07-27 2013-07-25 Compositions de toxine de tique

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017261603A Division AU2017261603B2 (en) 2012-07-27 2017-11-17 Tick toxin compositions

Publications (1)

Publication Number Publication Date
AU2013295770A1 true AU2013295770A1 (en) 2015-01-29

Family

ID=48916261

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2013295770A Abandoned AU2013295770A1 (en) 2012-07-27 2013-07-25 Tick toxin compositions
AU2017261603A Active AU2017261603B2 (en) 2012-07-27 2017-11-17 Tick toxin compositions
AU2019204773A Active AU2019204773B2 (en) 2012-07-27 2019-07-03 Tick toxin compositions

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2017261603A Active AU2017261603B2 (en) 2012-07-27 2017-11-17 Tick toxin compositions
AU2019204773A Active AU2019204773B2 (en) 2012-07-27 2019-07-03 Tick toxin compositions

Country Status (2)

Country Link
AU (3) AU2013295770A1 (fr)
WO (1) WO2014018724A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018141029A1 (fr) 2017-02-06 2018-08-09 Meat & Livestock Australia Limited Compositions immunostimulantes et leurs utilisations
AU2018407589A1 (en) * 2018-02-06 2020-09-10 Meat & Livestock Australia Limited Polypeptide, compositions and uses thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
KR100242671B1 (ko) 1991-03-07 2000-03-02 고돈 에릭 유전학적으로 처리한 백신 균주
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
US5350576A (en) 1991-09-13 1994-09-27 Mycogen Corporation Bacillus thuringiensis isolates for controlling acarides
WO1993013302A1 (fr) 1991-12-23 1993-07-08 Michael Zoche Moteur avec deshuileur
US5571515A (en) 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
IL125797A0 (en) 1996-02-28 1999-04-11 Bayer Ag Parapoxviruses which contain foreign dna their preparation and their use in vaccines
AU720801B2 (en) 1996-06-11 2000-06-15 University Of Technology, Sydney Paralysis tick neurotoxin
AUPO039596A0 (en) 1996-06-11 1996-07-04 Insearch Limited Paralysis tick neurotoxin
WO1998017799A1 (fr) 1996-10-23 1998-04-30 The Trustees Of The University Of Pennsylvania Immunotherapie et vaccins perfectionnes
US6194167B1 (en) 1997-02-18 2001-02-27 Washington State University Research Foundation ω-3 fatty acid desaturase
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
CN100352930C (zh) 1998-02-27 2007-12-05 宾夕法尼亚州立大学托管会 疫苗、免疫治疗剂及其应用方法
JP4673974B2 (ja) 1998-09-30 2011-04-20 ワイス・ホールディングズ・コーポレイション アジュバントとしての変異コレラホロトキシン
BR0009074A (pt) 1999-03-18 2002-01-02 Merck Patent Gmbh Proteìna para bloquear adesão de plaqueta
EP1130098A3 (fr) 2000-02-29 2003-09-10 Pfizer Products Inc. Osteorégulines mammifères
CA2449670A1 (fr) 2001-06-07 2002-12-12 Wyeth Holdings Corporation Formes mutantes de l'holotoxine du cholera utilisees comme adjuvant
KR100898648B1 (ko) 2001-06-07 2009-05-22 와이어쓰 홀딩스 코포레이션 보조제로서 콜레라 홀로톡신의 돌연변이체 형태
US7638134B2 (en) 2003-02-20 2009-12-29 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Insertion sites in fowlpox vectors

Also Published As

Publication number Publication date
AU2019204773B2 (en) 2021-02-18
AU2017261603B2 (en) 2019-07-18
AU2017261603A1 (en) 2017-12-21
WO2014018724A1 (fr) 2014-01-30
AU2019204773A1 (en) 2019-07-25

Similar Documents

Publication Publication Date Title
US11401498B2 (en) Bacillus based delivery system and methods of use
KR20190026834A (ko) 신규 보툴리눔 신경독소 및 그의 유도체
KR20190110605A (ko) 돼지 코로나바이러스 백신
AT508638A1 (de) Mimotope
AU2019204773B2 (en) Tick toxin compositions
Batanero et al. Purification, amino acid sequence and immunological characterization of Ole e 6, a cysteine-enriched allergen from olive tree pollen
NZ222717A (fr)
AU2005280742B2 (en) Immunogen and antivenom against violin spider venom
CN110041437B (zh) 一种无毒性破伤风毒素和诺维梭菌α毒素重组融合蛋白
US20150190499A1 (en) Bovine influenza c virus compositions
CN108904788B (zh) GnRH-防御素重组去势疫苗及其制备
US9464121B2 (en) Compositions and methods for treating erectile dysfunction
KR20180114684A (ko) 신규한 Stx2e 에피토프 단백질 및 이를 포함하는 백신 조성물
EP1213297B1 (fr) Peptides de la tachykinine, leurs peptides precurseurs et genes les codant
WO2015077442A2 (fr) Immunogènes de pollen de graminée ainsi que procédés et utilisations pour la modulation de la réponse immunitaire
KR101642499B1 (ko) 수용성 파스튜렐라 멀토시다 독소를 포함하는 재조합 융합 단백질, 면역원성 조성물 및 이의 제조방법
CN109942718B (zh) 一种无毒性破伤风毒素和产气荚膜梭菌β毒素重组融合蛋白
KR101942755B1 (ko) 멜리틴 유사 재조합 단백질의 제조방법과 이를 포함하는 피부용 조성물
JP2000514430A (ja) 精子抗原を含む免疫避妊組成物およびその使用方法
US7335759B2 (en) Recombinant immunogens for the generation of antivenoms to the venom of scorpions of the genus Centruroides
KR20220149174A (ko) 제2형 중증급성호흡기증후군 코로나바이러스의 수용체 결합 도메인 (SARS-CoV2 RBD)에 선택적으로 결합하는 신규한 폴리펩티드 및 이의 용도
WO2000020018A1 (fr) Conopeptides kappa-a et leurs utilisations
CN117897171A (zh) 包含源自非洲猪瘟病毒的抗原蛋白的用于预防非洲猪瘟的疫苗

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted